Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

9.460 -0.520 (-5.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 790,291
Open 9.980
Bid (Size) 9.450 (1)
Ask (Size) 9.900 (1)
Prev. Close 9.980
Today's Range 9.450 - 10.30
52wk Range 7.800 - 28.09
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?
Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data. 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill

Performance

YTD
-44.1%
-44.1%
1 Month
-36.1%
-36.1%
3 Month
-27.1%
-27.1%
6 Month
-48.2%
-48.2%
1 Year
-59.6%
-59.6%

More News

Read More
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results
Via Benzinga
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
Via Investor's Business Daily
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Discover the top movers in Friday's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
From Bicara Therapeutics Inc.
Via GlobeNewswire
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Bicara Therapeutics Inc. - Common Stock publicly traded?
Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
What is the current price of Bicara Therapeutics Inc. - Common Stock?
The current price of Bicara Therapeutics Inc. - Common Stock is 9.460
When was Bicara Therapeutics Inc. - Common Stock last traded?
The last trade of Bicara Therapeutics Inc. - Common Stock was at 05/28/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.